Core Viewpoint - Corvus Pharmaceuticals, Inc. will host a conference call and webcast on March 25, 2025, to provide a business update and report its fourth quarter and full year 2024 financial results [1]. Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel approach to immunotherapy for various cancer and immune diseases [3]. - The company's lead product candidate is soquelitinib, an investigational oral small molecule drug that selectively inhibits ITK [3]. - Corvus is also developing other clinical-stage candidates targeting a range of cancer indications [3]. Conference Call Details - The conference call can be accessed by dialing 1-800-717-1738 for domestic calls or 1-646-307-1865 for international calls, or through a provided link for instant access [2]. - A live webcast will be available via the investor relations section of the Corvus website, with a replay accessible for 90 days [2].

Core Insights - Corvus Pharmaceuticals has announced a Phase 2 clinical trial for soquelitinib, targeting autoimmune lymphoproliferative syndrome (ALPS), in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) [1][2] - The trial aims to evaluate the efficacy of ITK inhibition in improving immune system balance and reducing dysfunctional T cell accumulation in patients with ALPS [2][3] - Soquelitinib is also under investigation for other indications, including peripheral T cell lymphoma (PTCL) and atopic dermatitis, highlighting its potential versatility in treating various immune-related conditions [4][8] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel immunotherapy approach for cancer and immune diseases [8] - The company's lead product candidate, soquelitinib, is an investigational oral small molecule designed to selectively inhibit ITK, which plays a crucial role in T cell function [7][8] - Corvus is advancing soquelitinib through multiple clinical trials, including a registrational Phase 3 trial for PTCL and a Phase 1 trial for atopic dermatitis, with plans to initiate a Phase 1 trial for solid tumors in Q2 2025 [4][8] Disease Context - ALPS is a rare genetic disorder characterized by immune dysregulation, leading to symptoms such as lymphadenopathy, splenomegaly, and cytopenias, primarily caused by mutations in the Fas gene [5][6] - The condition typically manifests in early childhood and can lead to serious health complications, including autoimmune diseases and lymphoma, with no current cure available [2][5] - Current management strategies for ALPS involve empirical treatments aimed at alleviating symptoms and managing complications, including the use of corticosteroids and immunosuppressive medications [2][6]

Core Insights - Corvus Pharmaceuticals, Inc. is set to present a corporate overview and conduct one-on-one meetings with investors at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025 [1] - The presentation will be available via a live webcast, which can be accessed for 90 days post-event through the investor relations section of the Corvus website [2] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel immunotherapy approach for various cancers and immune diseases [3] - The company's lead product candidate is soquelitinib, an investigational oral small molecule drug that selectively inhibits ITK, with additional clinical-stage candidates targeting multiple cancer indications [3]

Core Insights - Corvus Pharmaceuticals announced new interim data from a Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis, showing a favorable safety and efficacy profile compared to placebo [1][2][3] Efficacy Data - In Cohort 1, 26% of patients receiving soquelitinib achieved IGA 0 or 1, and 37% achieved EASI 75, while none in the placebo group reached these endpoints after four weeks [3][4] - The trial included 16 patients in Cohort 1 and 10 patients in Cohort 2, with the latter showing improved results with a 200 mg once daily dose compared to the initial cohort [2][3] Safety Profile - No significant safety issues or clinically significant laboratory abnormalities were reported, with all patients in Cohort 2 completing the 28-day treatment [4] Trial Design - The Phase 1 trial is randomized, double-blind, and placebo-controlled, planned to enroll 64 patients with moderate to severe atopic dermatitis who have failed prior therapies [7] - The trial examines multiple dosing regimens, including 100 mg twice daily and 200 mg once daily, with a total of four cohorts [7][8] Future Outlook - The company plans to report full results from all cohorts in the second quarter of 2025 and is also advancing a Phase 3 trial for relapsed peripheral T cell lymphoma [2][4]

Core Viewpoint - Corvus Pharmaceuticals, Inc. will present a corporate overview and conduct one-on-one meetings with investors at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025 [1]. Group 1: Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ITK inhibition as a novel immunotherapy approach for various cancers and immune diseases [3]. - The company's lead product candidate is soquelitinib, an investigational oral small molecule drug that selectively inhibits ITK [3]. - Corvus is developing other clinical-stage candidates targeting a range of cancer indications [3]. Group 2: Event Details - Richard A. Miller, M.D., the president and CEO of Corvus Pharmaceuticals, will present on January 15 at 2:15 pm ET / 11:15 am PT [1]. - An audio webcast of the presentation will be available live and for 30 days post-event, accessible via the investor relations section of the Corvus website [2].

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile Data includes complete results from cohort 1 and initial results from cohort 2 Early exercise of common stock warrants from stockholder generates cash proceeds of approximately $12.7 million Company to host conference call and webcast today at 8:00 a.m. ET / 5:00 a.m. PT BURLINGAME, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today anno ...

BURLINGAME, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, will announce interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis tomorrow, December 18, 2024. The data will be provided in a press release and presented during a conference call and webcast. Conference Call, Webcast and Presentation Slides Corvus will h ...

BURLINGAME, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data highlighting the potential of soquelitinib, the Company’s lead ITK inhibitor program, as a novel approach to modulate tumor immunity. The data was published in npj Drug Discovery (part of the Nature portfolio of journals), an open access, international, peer-reviewed journal dedicated to publishing the highest quali ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Our " ...